CO5300517A1 - Monohidrato de cis-4-ciano-4-[3-(ciclopentiloxi)-4- metoxifenil]- ciclohexanocarboxilato de litio - Google Patents

Monohidrato de cis-4-ciano-4-[3-(ciclopentiloxi)-4- metoxifenil]- ciclohexanocarboxilato de litio

Info

Publication number
CO5300517A1
CO5300517A1 CO01005892A CO01005892A CO5300517A1 CO 5300517 A1 CO5300517 A1 CO 5300517A1 CO 01005892 A CO01005892 A CO 01005892A CO 01005892 A CO01005892 A CO 01005892A CO 5300517 A1 CO5300517 A1 CO 5300517A1
Authority
CO
Colombia
Prior art keywords
cis
cyano
lithium
cyclopentiloxi
cyclohexanocarboxylate
Prior art date
Application number
CO01005892A
Other languages
English (en)
Inventor
Kevin Scott Webb
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5300517A1 publication Critical patent/CO5300517A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto que es el monohidrato de la sal de litio de cis-4-ciano-4-[3-(ciclopentiloxi)-4-metoxifenil]ciclohexanocarboxilato.Una preparación farmacéutica que comprende el monohidrato de la sal de litio de cis-4-ciano-4-[3-(ciclopentiloxi)-4-metoxifenil]ciclohexanocarboxilato y un excipiente farmacéuticamente aceptable. Un método para preparar el monohidrato de la sal de litio de cis-4-ciano-4-[3-(ciclopentiloxi)-4-metoxifenil]ciclohexanocarboxilato, cuyo método comprende tratar una alícuota de la sal de litio anhidra con acetonitrilo y agua.
CO01005892A 2000-01-26 2001-01-26 Monohidrato de cis-4-ciano-4-[3-(ciclopentiloxi)-4- metoxifenil]- ciclohexanocarboxilato de litio CO5300517A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17812900P 2000-01-26 2000-01-26

Publications (1)

Publication Number Publication Date
CO5300517A1 true CO5300517A1 (es) 2003-07-31

Family

ID=22651319

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01005892A CO5300517A1 (es) 2000-01-26 2001-01-26 Monohidrato de cis-4-ciano-4-[3-(ciclopentiloxi)-4- metoxifenil]- ciclohexanocarboxilato de litio

Country Status (36)

Country Link
US (1) US6699903B2 (es)
EP (1) EP1250313B1 (es)
JP (1) JP2003520842A (es)
KR (1) KR20020073183A (es)
CN (1) CN1157371C (es)
AP (1) AP1432A (es)
AR (1) AR027273A1 (es)
AT (1) ATE344235T1 (es)
AU (1) AU3282201A (es)
BG (1) BG106959A (es)
BR (1) BR0107709A (es)
CA (1) CA2397758A1 (es)
CO (1) CO5300517A1 (es)
CY (1) CY1108515T1 (es)
CZ (1) CZ20022590A3 (es)
DE (1) DE60124221T2 (es)
DK (1) DK1250313T3 (es)
DZ (1) DZ3285A1 (es)
EA (1) EA200200791A1 (es)
EG (1) EG24065A (es)
ES (1) ES2273804T3 (es)
HK (1) HK1051030A1 (es)
HU (1) HUP0204150A3 (es)
IL (1) IL150400A0 (es)
MA (1) MA25652A1 (es)
MX (1) MXPA02007300A (es)
MY (1) MY122802A (es)
NO (1) NO20023378L (es)
NZ (1) NZ519799A (es)
OA (1) OA12159A (es)
PE (1) PE20011040A1 (es)
PL (1) PL356832A1 (es)
PT (1) PT1250313E (es)
SK (1) SK10942002A3 (es)
WO (1) WO2001055094A1 (es)
ZA (1) ZA200205925B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011802D0 (en) * 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677776B2 (en) * 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
UA67753C2 (uk) * 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот

Also Published As

Publication number Publication date
BR0107709A (pt) 2002-11-19
MY122802A (en) 2006-05-31
CZ20022590A3 (cs) 2003-01-15
CN1395556A (zh) 2003-02-05
CY1108515T1 (el) 2014-04-09
IL150400A0 (en) 2002-12-01
DZ3285A1 (fr) 2001-08-02
EP1250313A4 (en) 2005-09-21
PE20011040A1 (es) 2001-10-31
OA12159A (en) 2006-05-08
AR027273A1 (es) 2003-03-19
BG106959A (en) 2003-05-30
AU3282201A (en) 2001-08-07
AP2002002566A0 (en) 2002-06-30
HUP0204150A3 (en) 2003-05-28
WO2001055094A1 (en) 2001-08-02
SK10942002A3 (sk) 2002-11-06
EP1250313B1 (en) 2006-11-02
US6699903B2 (en) 2004-03-02
NO20023378D0 (no) 2002-07-12
PL356832A1 (en) 2004-07-12
EP1250313A1 (en) 2002-10-23
MXPA02007300A (es) 2002-11-29
AP1432A (en) 2005-06-20
CN1157371C (zh) 2004-07-14
NO20023378L (no) 2002-07-12
ZA200205925B (en) 2003-11-21
DK1250313T3 (da) 2007-02-12
MA25652A1 (fr) 2002-12-31
NZ519799A (en) 2004-04-30
DE60124221D1 (de) 2006-12-14
EA200200791A1 (ru) 2002-12-26
JP2003520842A (ja) 2003-07-08
US20030032670A1 (en) 2003-02-13
HUP0204150A2 (hu) 2003-04-28
ATE344235T1 (de) 2006-11-15
KR20020073183A (ko) 2002-09-19
PT1250313E (pt) 2007-01-31
ES2273804T3 (es) 2007-05-16
DE60124221T2 (de) 2007-09-13
CA2397758A1 (en) 2001-08-02
HK1051030A1 (zh) 2003-07-18
EG24065A (en) 2008-05-08

Similar Documents

Publication Publication Date Title
GB0019283D0 (en) Organic compounds
ES2137862B1 (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
GEP20043238B (en) Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
NO950297L (no) Prolinamidderivater
NO20015664L (no) Nye farmasöytisk aktive forbindelser
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
SI1435915T1 (sl) Oralne dozirne oblike za propiverin ali njegove farmacevtsko sprejemljive soli s podaljšanim sproščanjem učinkovine
BR0114896A (pt) Preparação contendo nateglinida, e, método para produzir a mesma
AR079399A2 (es) Procedimientos para preparar bifenazato
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
EA199900709A1 (ru) Таблетка для глотания, включающая в себя парацетамол
CO5300517A1 (es) Monohidrato de cis-4-ciano-4-[3-(ciclopentiloxi)-4- metoxifenil]- ciclohexanocarboxilato de litio
CO4950550A1 (es) Procedimiento
EA200400417A1 (ru) Новые безводные кристаллические формы габапентина
SE9900190D0 (sv) New compounds
BR9400020A (pt) Composto, processo para sua preparação, composicões farmacêuticas e uso
DE69608699T2 (de) Fluorsubstituierte benzoylpropionsaürederivate
GB0006897D0 (en) Medicaments
AR025791A1 (es) Forma de dosificacion oral
NO20032035L (no) Terapeutiske midler for keratokonjuktivitis sykdommer omfattende farnesyleddiksyre som aktiv ingrediens
ECSP055749A (es) Formulacion de tramadol de liberacion sostenida con eficacia de 24 horas
WO2001043692A3 (en) SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID
ECSP003602A (es) PRODUCTOS DE LA DROGA ß- CARBOLINE
ITMI20001253A0 (it) Procedimento per il trattamento di un tappero con una composizione comprendente un tensioattivo non irritante

Legal Events

Date Code Title Description
FC Application refused